SELLAS Life Sciences Group , a development-stage biopharmaceutical company focused on developing innovative products to treat cancer, has made four executive appointments to provide medical, clinical, commercial and financial expertise to support the development of its unique product, the galinpepimut-S immunotherapeutic anti-cancer treatment. — William Pollett has been appointed SELLAS' Chief Financial Officer.
